Billing and Reimbursement
MOZOBILDirect Reimbursement Assistance
Sanofi has a reimbursement support program to provide you with a 1-stop resource for all patient access and reimbursement needs. MOZOBILDirect is available weekdays (Monday - Friday) from
9:00 AM to 8:00 PM Eastern Time.
MOZOBILDirect can provide your office with assistance with the following complimentary services:
- to research coverage for MOZOBIL (plerixafor injection)
Coding and billing assistance
- to ensure accurate codes are used before claim submission
Claim/denial and appeal assistance
- to research appeal strategies and provide supporting documentation for the appeals process
Prior authorization assistance
- to research steps required to obtain authorization, if needed
Patient Assistance Program
- to provide assistance to patients with no insurance coverage who meet program criteria
- with permission, counselors will contact patients directly and work with both patients and providers
to determine if there are alternative services available
1-877-4MOZOBIL (1-877-466-9624), option 3
Hours of operation:
Monday through Friday
9:00 AM - 8:00 PM EST
|Trade / Brand Name
||Mozobil ® (plerixafor injection)
||Each single-use vial is filled to deliver 1.2 mL of 20 mg/mL solution
Click Here for more billing information.
Mozobil (plerixafor injection) is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).
Important Safety Information for Mozobil (plerixafor injection)
- Mozobil is contraindicated in patients with a history of hypersensitivity to Mozobil.
- Anaphylactic shock and serious hypersensitivity reactions, some of which have been life-threatening, have occurred in patients receiving Mozobil. Observe patients for signs and symptoms of hypersensitivity during and after Mozobil administration for at least 30 minutes and until clinically stable. Only administer Mozobil when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions.
- Mozobil may cause mobilization of leukemic cells and subsequent contamination of the apheresis product. Therefore, Mozobil is not intended for HSC mobilization and harvest in patients with leukemia.
- Mozobil in conjunction with G-CSF increases circulating leukocytes and HSC populations. White blood cell counts should be monitored during treatment.
- Thrombocytopenia has been observed in patients receiving Mozobil. Platelet counts should be monitored in patients who receive Mozobil and then undergo apheresis.
- In patients treated with Mozobil in combination with G-CSF for HSC mobilization‚ tumor cells may be released from the marrow and subsequently collected in the leukapheresis product. The effect of potential reinfusion of tumor cells has not been well-studied.
- The effect of Mozobil on spleen size was not specifically evaluated in clinical studies. Individuals receiving Mozobil in combination with G-CSF who report left upper abdominal pain and/or scapular or shoulder pain should be evaluated for splenic integrity.
- Mozobil may cause fetal harm when administered to a pregnant woman. Plerixafor is teratogenic in animals. There are no adequate and well-controlled studies in pregnant women using Mozobil. Advise women of childbearing potential to avoid becoming pregnant while receiving treatment with Mozobil.
- The most common adverse reactions (≥10%) during HSC mobilization and apheresis were: diarrhea (37%), nausea (34%), fatigue (27%), injection site reactions (34%), headache (22%), arthralgia (13%), dizziness (11%), and vomiting (10%). The majority of these adverse reactions were Grade 1 or 2.
Please see full Prescribing Information
- Mozobil (plerixafor injection) Full Prescribing Information. Genzyme Corporation; 2013.